Clinical Investigation of the Freedom SOLO Stentless Heart Valve

March 5, 2024 updated by: Corcym S.r.l
This is a trial to demonstrate the safety and effectiveness of the Freedom SOLO heart valve when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Freedom SOLO study is a prospective, non-randomized, multicenter trial on the Freedom SOLOvalve implanted in patients requiring aortic valve replacement. The study was conducted at 18 centers in Europe.

The study was based on single sample hypothesis testing that allows comparison of observed morbid event rates to objective performance criteria (OPCs). Based on the guidelines established by the U.S. Food and Drug Administration (FDA), the minimum sample size for this study was 800 valve-years, which is the minimum amount of data needed to test against the OPC of 1.2 %/patient-year.

Study Type

Interventional

Enrollment (Actual)

702

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Wien, Austria, 1030
        • Krankenhaus Hietzing
      • Wien, Austria, 1090
        • Medical University Vienna
  • Belgium
      • Bruxelles, Belgium, 1200
        • St. Luc Hospital
      • Gent, Belgium, 9000
        • University Hospital Gent
  • France
      • Rennes, France, 35033
        • Hôpital Pontchaillou - CHU
      • Tours, France, 37000
        • Hôpital Trousseau - CHRU
  • Germany
      • Bad Neustadt An Der Saale, Germany, 97616
        • Herz- und Gefäß-Klinik GmbH
      • Berlin, Germany, 10117
        • Charite Hospital
      • Dresden, Germany, 01307
        • Herzzentrum Dresden Universitätsklinik an der Technischen Universität Dresden
      • Erlangen, Germany, 91054
        • Universitätsklinikum Erlangen, Klinik für Herzchirurgie
  • Italy
      • Massa, Italy, 54100
        • Ospedale del Cuore, Fondazione G. Monasterio
      • Treviso, Italy, 31100
        • Ospedale "S. Maria di Ca' Foncello"
      • Udine, Italy, 33100
        • Ospedale S. Maria Della Misericordia
  • Netherlands
      • Amsterdam, Netherlands, 1100 DD
        • Academisch Medisch Centrum
      • Eindhoven, Netherlands, 5623 EJ
        • Catharina hospital
      • Enschede, Netherlands, 7513 ER
        • Medisch Spectrum Twente, Thoraxcentrum
      • Nijmegen, Netherlands, 6500 HB
        • University Hospital St. Radboud
  • Portugal
      • Porto, Portugal, 4200-319
        • Hospital S. João
  • Switzerland
      • Bern, Switzerland, 3010
        • Inselspital, University Hospital Berne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The patient is male or female 18 years old or older.
  • The patient is willing to sign the informed consent.
  • The patient which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
  • Any patient amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
  • The patient is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
  • Patient will be available to the investigator(s) for postoperative follow-up beyond one year.

Exclusion Criteria:

  • The patient has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
  • The patient requires a double or triple valve replacement (a valve repair is not considered an exclusion criterion).
  • The patient has a previously implanted SOLO valve, within the clinical study, that requires replacement.
  • The patient has active endocarditis.
  • The patient is or will be participating in a concomitant research study of an investigational product.
  • The patient is a minor, intravenous drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent.
  • The patient has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the patient.
  • The patient is pregnant or lactating.
  • Patients with congenital bicuspid aortic valve.
  • Patients are known to be noncompliant or are unlikely to complete the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Freedom SOLO stentless valve
Prospective data collection on the outcomes in patients treated with the CE Marked Freedom Solo Valve within the approved indication.
Device: Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis
The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The complication and survival rates for the Freedom SOLO stentless valve.
Time Frame: up to 1 year
Safety of the Freedom SOLO was evaluated based on the following adverse events related to cardiac valve replacement: valve thrombosis, thromboembolism, bleeding, anticoagulant-related bleeding, paravalvular leak, endocarditis, clinically significant hemolysis, nonstructural dysfunction, structural valve deterioration, reoperation, explant, and death.
up to 1 year
The complication and survival rates for the Freedom SOLO stentless valve.
Time Frame: up to 5 year
Safety of the Freedom SOLO was evaluated based on the following adverse events related to cardiac valve replacement: valve thrombosis, thromboembolism, bleeding, anticoagulant-related bleeding, paravalvular leak, endocarditis, clinically significant hemolysis, nonstructural dysfunction, structural valve deterioration, reoperation, explant, and death.
up to 5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemodynamic performance of the Freedom SOLO stentless valve: transvalvular peak and mean pressure gradients
Time Frame: up to 5 year
Decrease of transvalvular peak and mean pressure gradients from preoperative to follow up
up to 5 year
Hemodynamic performance of the Freedom SOLO stentless valve: effective orifice area (EOA) in cm2 by transthoracic echocardiography
Time Frame: up to 5 year
Increase of effective orifice area (EOA) from preoperative to follow up
up to 5 year
Hemodynamic performance of the Freedom SOLO stentless valve: EOA index (EOAI cm2/m2).
Time Frame: up to 5 year
Increase of effective orifice area index from preoperative to follow up.
up to 5 year
Hemodynamic performance of the Freedom SOLO stentless valve: cardiac output (CO) Clinically significant improvement in overall patient condition.
Time Frame: up to 5 year
Improvement of Cardiac Output
up to 5 year
Hemodynamic performance of the Freedom SOLO stentless valve: cardiac index (CI) Clinically significant improvement in overall patient condition.
Time Frame: up to 5 year
Improvement of Cardiac Index
up to 5 year
Hemodynamic performance of the Freedom SOLO stentless valve: regurgitation Clinically significant improvement in overall patient condition.
Time Frame: up to 5 year
Evaluation of regurgitation, location and severity
up to 5 year
Preoperative and postoperative NYHA functional classifications
Time Frame: Preoperatively, after the procedure (1 week), 3-6 months, 12 months and annually thereafter
NYHA functional classification data is presented as the number and percentage of patients in each functional class.
Preoperatively, after the procedure (1 week), 3-6 months, 12 months and annually thereafter

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Corcym S.r.l

Investigators

  • Principal Investigator: Markus Thalmann, MD, KH Hietzing Wien

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2009

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2017

Study Registration Dates

First Submitted

April 3, 2009

First Submitted That Met QC Criteria

April 3, 2009

First Posted (Estimated)

April 6, 2009

Study Record Updates

Last Update Posted (Estimated)

March 6, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • V10604

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe